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The polyanionic nature of oligonucleotides and their enzymatic
degradation present challenges for the use of siRNA in research
and therapy; among the most notable of these is clinically relevant
delivery into cells. To address this problem, we designed and
synthesized the first members of a new class of guanidinium-rich
amphipathic oligocarbonates that noncovalently complex, deliver,
and release siRNA in cells, resulting in robust knockdown of target
protein synthesis in vitro as determined using a dual-reporter sys-
tem. The organocatalytic oligomerization used to synthesize these
co-oligomers is step-economical and broadly tunable, affording an
exceptionally quick strategy to explore chemical space for optimal
siRNA delivery in varied applications. The speed and versatility of
this approach and the biodegradability of the designed agents
make this an attractive strategy for biological tool development,
imaging, diagnostics, and therapeutic applications.
amphipathic co-oligomers ∣ nanoparticles ∣ oligonucleotide delivery ∣
biodegradable oligomers ∣ organocatalysis
RNA interference (RNAi) is an emerging technology that isrevolutionizing many strategic approaches to biochemical
pathway analysis, drug discovery, and therapy (1–6). As part of
the RNAi pathway, small interfering RNAs (siRNAs) induce
post-transcriptional, sequence-specific gene silencing utilizing
endogenous intracellular machinery to selectively suppress gene
expression and, thereby, reduce target protein synthesis (7). The
net effect is equivalent to protein inhibition without the use of
small molecule inhibitors. The specificity of RNAi also allows one
to make inhibitors against previously undruggable targets. Both
the ubiquity of the RNAi pathway within the body and the ease
with which siRNA can be used to suppress a specific target of
interest have made siRNAs a promising class of molecules for the
treatment of cancer, viral infections, ocular disorders, and genetic
diseases (5). In 2004, the first siRNA-based therapy entered
Phase 1 clinical trials (4). Since then, several other RNAi-based
therapies have reached clinical evaluation for a number of indi-
cations including cancer, viral infections, and genetic skin disor-
ders (5, 8, 9). Notwithstanding this progress, formidable chal-
lenges remain for the application of RNAi technology in basic
research and therapy, the most fundamental of which is delivery
of siRNA across biological barriers.
The siRNAs are double-stranded RNA molecules typically
consisting of a 19–23 base-paired region with two 3′ overhanging
nucleotides. It is polyanionic, polar, and large (ca. 13 kDa), com-
pared to small molecule therapeutics. These physical properties
suppress or prevent its unassisted passage through nonpolar
membranes and, thus, its access to the intracellular RNA-induced
silencing complex (RISC) components required for target protein
knockdown (6). This problem is further exacerbated by siRNA’s
susceptibility to enzymatic degradation (i.e., RNases) (3). To ad-
dress these problems, two strategies have been pursued: develop-
ment of noncharged and nonbiodegradable siRNA surrogates
(10) and, more directly, development of delivery vehicles and
strategies that would enable or enhance the entry of siRNA itself.
Several siRNA delivery technologies have been reported thus far,
including direct covalent conjugation of siRNA to lipids, pep-
tides, or to aptamers; and noncovalent complexation of siRNA
with polymers, biopolymers, nanotubes, lipid-based vehicles (e.g.,
lipopolyplexes, stable nucleic acid lipid nanoparticles), cyclodex-
trin polymer-based nanoparticles, fusion proteins, membrane
translocation-modified magnetic nanoparticles, and antibody—
protamine conjugates (4, 6, 11–22).
In 2000, we reported an extensive reverse engineering
effort directed at the highly cationic HIV-Tat 9-mer peptide
(RKKRRQRRR), showing that its ability to enter cells is related
to its arginine content and, more specifically, to the number and
array of its guanidinium groups (23). This finding led to the
design of oligoarginine and guanidinium-rich peptoid cell pene-
trating agents and, subsequently, a wide range of designed non-
peptidic agents, more generally and accurately dubbed molecular
transporters, differing in backbone structure but uniformly incor-
porating the key guanidinium head groups (24). These more
synthetically accessible homo-oligomeric transporters performed
as well as and often better than the hetero-oligomeric Tat 9-mer
in in vitro and in vivo studies. We and others have since shown
that these guanidinium-rich molecular transporters can enable or
enhance the delivery of a variety of cargos, including small mo-
lecules, metals, imaging agents, peptides, plasmids, and proteins
across biological barriers, such as cell membranes and the stratum
corneum, the latter as part of a clinical trial (24, 25). Recently, we
developed an oligomerization strategy that generates unique gua-
nidinium-rich homo-oligocarbonate molecular transporters in an
exceptionally step-economical fashion (one to two steps) through
a metal-free organocatalytic ring-opening oligomerization reac-
tion (26). With this strategy, the length of the oligomer (degree
of polymerization, DP) can be easily tuned by varying the ratio of
monomer to initiator in the oligomerization step. The guanidi-
nium-rich oligocarbonate molecular transporters have narrow
molecular weight distributions (Mw∕Mn ¼ 1.1 − 1.2), are repro-
ducibly formed over a range of scales (50 mg to 2.5 g), and, like
oligoarginines, readily enter cells. Significantly, this oligomeriza-
tion strategy can also be deployed to produce co-oligomers of
widely varied composition and therefore properties, again in
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one to two steps through the use of two or more monomers in-
corporating different side chains (27–29).
We reasoned that the polycationic nature of guanidinium-rich
oligocarbonates, if mixed with additional functionality for cell
penetration, could be exploited to noncovalently complex and de-
liver oligonucleotides into cells. More specifically, we hypothe-
sized that amphipathic carbonate co-oligomers, composed of
guanidinium-rich side chains to bind siRNA through electrostatic
and hydrogen-bonding associations and hydrophobic side chains
to facilitate packing and cellular entry (Fig. 1A), would serve as
effective siRNA complexation and delivery vehicles. Requiring
only one to two steps to prepare, the metal-free syntheses of these
co-oligomers are uniquely short and facile, thereby allowing one
to rapidly synthesize, test, and tune co-oligomers for uptake and
offering a distinct advantage over lengthy stepwise synthesis. This
co-oligomerization strategy would also be readily amenable to
the introduction of targeting elements as the initiator moiety.
A further advantage of this approach is that these new carbonate
co-oligomers would be biodegradable, a feature that could serve
to affect both cargo release and transporter clearance. The meth-
od of synthesis, the length of these co-oligomers, the use of the
guanidinium group as a cationic complexing moiety and, notably,
the biodegradable nature of the oligocarbonate backbone are
rare in the siRNA delivery field, and their combination is unique.
The distinct advantages offered by this strategy and the speed
with which information on siRNA complexation and delivery
could be acquired prompted the investigation described herein.
We report the study of the synthesis and evaluation of a series of
carbonate co-oligomers designed to systematically probe the
functionality and factors required for effective complexation, de-
livery, and release of siRNA.
Results and Discussion
Synthesis of the Guanidinium-Rich Amphipathic Carbonate Co-oligo-
mer Transporters. The initial target set of carbonate co-oligomers
was selected to explore the influence of structural variables (e.g.,
molecular weight, hydrophobicity, ratio of lipid to guanidinium
content) on complexation and cellular uptake. As these are the
first guanidinium-rich amphipathic co-oligocarbonate transpor-
ters to be studied, information on the optimal lipid side chain
for siRNA delivery was not known but was expected to be rapidly
addressable through the systematic use of monomers incorporat-
ing simple, stable and biocompatible lipid side chains (ethyl, hex-
yl, or dodecyl, Fig. 1B: 2–4). Cholesterol-incorporating monomer
5 was also included to explore the role of more complex polycyclic
lipids in both co-oligomer synthesis and performance. Further
exemplifying the flexibility and speed of this strategy, the mono-
mers were efficiently accessed by conversion of the cyclic carbo-
nate carboxylic acid 1 to an acid chloride, followed by esterifica-
tion with selected lipid alcohols (30).
Co-oligomerizations were then conducted using both the re-
quisite hydrophobic monomer and the previously reported gua-
nidine-protected monomer 6 (Fig. 1C) (26). A range of DPs
(oligomer lengths) was targeted including “short” (Table 1, m ¼
n ¼ approximately 4), “medium” (m ¼ n ¼ approximately 8),
and “long” (m ¼ n ¼ approximately 18) co-oligomers. For the
hexyl series, co-oligomers with varied lipid to guanidinium ratios
were also synthesized to determine how this ratio influences siR-
NA complexation and delivery. Benzyl alcohol, which serves as a
useful handle for characterization purposes, was initially chosen
as the initiator. As a further demonstration of the rapid tuning
and versatility of this strategy, later iterations incorporated the
more complex poly(ethylene glycol) methyl ether (PEG), to ex-
plore its effect on complexation and biodistribution. Block co-
oligomers were synthesized by mixing the requisite initiator first
with each one of the hydrophobic monomers 2–5 in the presence
of both the thiourea catalyst (TU) and catalytic base (1,8-diaza-
bicycloundec-7-ene, DBU). When the first lipid block had
formed, guanidine-protected monomer 6 was added, leading to
incorporation of the second protected-guanidine block. Alterna-
tively, statistical co-oligomers were synthesized by using a mixture
of the hydrophobic monomer and protected-guanidine monomer
at the start of the reaction. Deprotection of the guanidine func-
tionality with trifluoroacetic acid (TFA) in either the block or sta-
tistical co-oligomers yielded the desired amphipathic carbonate
co-oligomers (Table 1). The synthesized amphipathic carbonate
co-oligomers represent variations in overall length (DP ¼
degree of polymerization), initiator moiety, hydrophobic sub-
structure, and hydrophobic to guanidinium ratio, collectively
allowing for systematic examination of their ability to noncova-
lently complex, deliver, and release siRNA.
Characterization of siRNA∶Co-oligomer Complexes. As these guani-
dinium-rich amphipathic carbonate co-oligomers represent a new
class of delivery vehicles, our initial focus was to determine
whether they would spontaneously form complexes with siRNA.
A gel shift assay was used for this purpose. To form the
siRNA∶co-oligomer complexes, a solution of siRNA in phos-
phate buffered saline (PBS) was added to a solution of co-oligo-
mer in PBS to obtain siRNA∶co-oligomer molar ratios of 1∶1,
1∶5, 1∶10, and 1∶25. The resulting solutions were incubated at
room temperature to allow time for complex formation (30 min).
The complexes were then loaded onto an agarose gel, fractio-
nated, and subsequently stained with ethidium bromide. The
Fig. 1. General structure and synthesis of the guanidinium-rich amphipathic carbonate co-oligomers. (A) General structure of the amphipathic carbonate
block co-oligomers. (B) Synthesis of the hydrophobic monomers from carboxylic acid 1. (C) Amphipathic block co-oligomers were synthesized by organo-
catalytic ring opening oligomerization of the monomers, followed by guanidine deprotection with TFA. The scheme depicts the synthesis for a block
co-oligomer. Statistical co-oligomers were synthesized by adding both monomers simultaneously at the start of the reaction.
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ability of each co-oligomer to noncovalently complex with siRNA
at a given molar ratio was assessed by the degree to which
the migration of the siRNA toward the positive electrode was
inhibited (SI Appendix, Fig. S1). The highly hydrophobic co-oli-
gomers 8d and cholesterol-containing 11b were insoluble in PBS
and, therefore, were ineffective in complexing siRNA under the
conditions tested. All other co-oligomers with an approximate
lipid∶guanidinium ratio of 1 or less formed complexes with
siRNA.
Gel electrophoresis was also used to assess the hydrolytic stabi-
lity of the siRNA∶co-oligomer complexes. As had been shown
previously for the guanidinium-only carbonate oligomers, the car-
bonate backbone is shelf stable as a solid but, as desired for cargo
release after cell entry, it hydrolyses with a half-life of about 8 h in
Hepes-buffered saline (pH7.4, 37 °C) (26).Weanticipated that the
siRNA∶co-oligomer complexes would be similarly stable during
cellular entry but subsequently degrade with the release of free
siRNA. In a hydrolytic stability assay in the absence of cells, the
releaseof free siRNAcouldbedetectedbyethidiumbromide stain-
ing in a gel shift assay. The siRNA∶co-oligomer complexes were
incubated for various amounts of time in PBS (pH ¼ 7.4, 37 °C)
and then loaded onto a gel and fractionated (SI Appendix,
Fig. S2). As expected, subsequent staining revealed a stronger un-
complexed siRNA band as the incubation time in PBS increased
(8–24 h). While not quantitative, this assay demonstrates that the
siRNA∶co-oligomer complexes examined in this study generally
stay intact during incubation (for at least 4 h), with differences
in hydrolytic stability depending on the tunable composition of
the co-oligomer. This period is attractive for cell-uptake studies
as the complexes are internalized within minutes and before
substantial degradation occurs. By 24 h, the complex, regardless
of co-oligomer identity, is almost fully degraded. The timing of
the siRNA∶co-oligomer complex degradation allowed for rapid
evaluation of uptake and release in this inaugural study.More gen-
erally, this tunable property could also be used tominimize toxicity
(seebelow)or to facilitate local delivery and release, therebyavoid-
ing off-target effects from unintentional systemic exposure.
Dynamic light scattering (DLS) was used to analyze the aver-
age diameter of the siRNA∶co-oligomer complexes. For these
experiments, complexes were formed at the same charge ratio
as used in the in vitro siRNA delivery experiments (charge ratio
of 4.8/1 +/-) (see below). While all co-oligomers examined by
DLS-formed complexes whose sizes could be measured immedi-
ately upon mixing with siRNA, some of the co-oligomers, includ-
ing a guanidinium-only oligomer, formed aggregates that could
not be accurately sized and generally were found to be either
less effective or ineffective in delivering siRNA (see below).
The size of the siRNA∶co-oligomer complexes, which is a tunable
function of co-oligomer type and siRNA∶co-oligomer ratio, ran-
ged in this study from approximately 200 nm in diameter to ap-
proximately 1.5 μm (SI Appendix, Table S1). These are average
sizes and by filtration one can obtain smaller (<200 nm) or larger
particle sizes. Over the course of the hour measurement period,
some of the co-oligomer complexes increased in size, a phenom-
enon that has been observed previously in the complexation of
polynucleotides with oligoguanidiniums (31). Solutions of only
the co-oligomer without siRNA did not form measurable parti-
cles at the concentrations used for siRNA∶co-oligomer complex
formation. Size measurements were not optimized for this study,
though they can be further modified by varying the ratio of co-
oligomer to siRNA by mixing two distinct co-oligomers with one
another before mixing with siRNA, or by utilizing PEG initiated
co-oligomers (see below). These results demonstrate that the
siRNA∶co-oligomer complex size can be tuned by modifying
the identity of the amphipathic co-oligomer.
Guanidinium-Rich Amphipathic Carbonate Co-oligomer-Mediated
siRNA Delivery In Vitro. The amphipathic carbonate co-oligomers
were then screened for their ability to deliver and release siRNA
intracellularly. To examine the siRNA∶co-oligomer complexes, a
dual fluorescent protein reporter assay was used, allowing one
protein to be selectively suppressed by its siRNA while the other
serves as an internal control. Immortalized human keratinocytes
(HaCaTs) were transduced with two distinct lentiviral reporter
constructs; one expresses enhanced green fluorescent protein
(EGFP), and the other consists of tandem luciferase (Luc2) and
tomato fluorescent protein (tdTOM) (Luc2/tdTOM) (32). The
siRNA-entitled CBL3 (33) targets the Luc2/tdTOM fusion
construct and would therefore reduce, if successfully delivered,
the red fluorescent protein expression without affecting the
green fluorescent protein expression. The EGFP reporter is
valuable as a control for potential nonspecific effects of siRNA
administration.
In these experiments, siRNA∶co-oligomer complexes were
formed by mixing together siRNA and co-oligomer solutions at
a positive to negative (+/−) charge ratio of 4.8∶1, which was held
constant to allow for comparisons of different co-oligomers. The
resultant complex was incubated at room temperature for 30 min
Table 1. Representative synthesized guanidinium-rich amphipathic carbonate co-oligomers. Co-oligomer descriptors refer to the
hydrophobic side chain (E ¼ ethyl, H ¼ hexyl, D ¼ dodecyl, Chol ¼ cholesterol) and to the guanidinium group (G) used, followed by
numbers that reflect the average number of the respective monomers in the oligomer. The n and m refer to Fig. 1C
Co-oligomer number Co-oligomer name n m R Initiator Type Mw∕Mn*
7a E∶G 5∶5 5 5 ethyl benzyl block 1.46
7b E∶G 8∶9 8 9 ethyl benzyl block 1.30
7c E∶G 19∶19 19 19 ethyl benzyl block 1.42
8a H∶G 4∶4 4 4 hexyl benzyl block 1.46
8b H∶G 8∶9 8 9 hexyl benzyl block 1.33
8c sH∶G 9∶9 9 9 hexyl benzyl statistical 1.26
8d H∶G 10∶4 10 4 hexyl benzyl block 1.20
8e H∶G 4∶10 4 10 hexyl benzyl block 1.15
8f H∶G 17∶16 17 16 hexyl benzyl block 1.35
9a D∶G 4∶4 4 4 dodecyl benzyl block 1.61
9b D∶G 4.5∶5 4.5 5 dodecyl benzyl block 1.33
9c sD∶G 4∶4 4 4 dodecyl benzyl statistical 1.37
9d D∶G 7∶7 7 7 dodecyl benzyl block 1.47
9e D∶G 18∶17 18 17 dodecyl benzyl block 1.47
10 PEG-D∶G 2.5∶3 2.5 3 dodecyl PEG-2000 block 1.31
11a Chol∶G 3∶7 3 7 cholesterol benzyl block 1.39
11b Chol∶G 7∶7 7 7 cholesterol benzyl block 1.37
12 G8 — 8 — benzyl block 1.18
*Mw∕Mn was determined on the Boc-protected co-oligomer.
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and then added to cells along with Dulbecco’s modified Eagle
medium (DMEM). Cells were incubated with the complex for
4 h, after which the complex was removed and replaced with fresh
media, and the cells allowed to incubate for an additional 3 d.
Treated cells were analyzed by flow cytometry for both EGFP
and tdTOM expression. The coefficient from the division of
tdTOM by EGFP was then normalized to untreated cells to de-
termine a percent tdTOM expression that is specific for a reduc-
tion in tdTOM relative to EGFP.
All of the amphipathic carbonate block co-oligomers were ef-
fective in complexing, delivering, and releasing siRNA, though to
varying degrees and with clearly discernible trends, some unan-
ticipated (Fig. 2A). As expected, siRNA itself did not enter cells.
Comparison of the ethyl, hexyl, and dodecyl compounds series
revealed that, for an overall oligomer length, dodecyl-incorpor-
ating co-oligomers outperform their hexyl counterparts, which
in turn outperform their ethyl counterparts. Significantly, certain
dodecyl-incorporating co-oligomers achieved an average of 86%
knockdown of the target protein, with >90% in some experi-
ments. Interestingly, shorter co-oligomers outperform their long-
er counterparts within each hydrophobic side chain series. The
statistical co-oligomers can also effectively deliver siRNA. How-
ever, they do not perform consistently relative to their block
counterparts (the statistical hexyl co-oligomer 8c outperforms
block co-oligomer 8b, while the statistical dodecyl co-oligomer
9c performs similarly to block co-oligomer 9a). Exchange of the
counterion from TFA to chloride does not significantly change
siRNA uptake and release. As expected, the delivery into cells
of a control siRNA targeting an irrelevant gene using the best
performing co-oligomer does not result in reduction of tdTOM
expression. In addition, a guanidinium-only homo-oligomer with
DP ¼ 8ð12Þ also showed no reduction in tdTOM expression, in-
dicating the importance of both hydrophobic and guanidinium
groups for effective siRNA delivery. In both untreated and co-oli-
gomer treated cells, the level of expression of green fluorescent
protein for a given experiment remained relatively constant, in-
dicating no nonspecific effects on green fluorescent protein ex-
pression (SI Appendix, Fig. S3). As we were initially interested
in the potential of using this technology for as yet unaddressed
indications involving intradermal delivery, co-oligomers were
screened in the absence of serum. However, dosing siRNA∶co-
oligomer complex of 9a in serum-containing media results in
effective knockdown (64%), although at a lower level than ser-
um-free media (86%). Efforts to optimize for serum stability were
not further investigated in this study.
The amphipathic co-oligomers have batch-to-batch reproduci-
bility. Though 9a and 9b have slightly different average molecular
weights and different molecular weight distributions, the tdTOM
knockdown resulting from the siRNA∶co-oligomer complexes of
each of these co-oligomers is within error of one another.
A dose response assay was performed for several of the more
effective co-oligomers (Fig. 2B: 8a, 9a, and 9d). While both 9a
and 9d outperform 8a at the highest dose, 8a has better activity
at lower doses of siRNA∶co-oligomer complex.
To further illustrate the specific knockdown at the cellular le-
vel, the dual fluorescence reporter HaCaT cells described above
were treated with siRNA∶co-oligomer complex and then visua-
lized with a fluorescence microscope (Fig. 3). The images show
a clear correlation between the flow cytometry results and fluor-
escent cell images. Untreated HaCaTcells exhibited high levels of
both EGFP and tdTOM expression, and all of the amphipathic
co-oligomers tested exhibited a selective reduction in tdTOM
while maintaining strong EGFP levels. Furthermore, the relative
td-TOM knockdown observed for the various amphipathic co-
oligomers mirrored the flow cytometry results; 8b, which had a
more moderate level of knockdown, exhibited some observable
red fluorescence whereas 8a, 9a, and 9d, all co-oligomers which
exhibit >80% tdTOM knockdown by flow cytometry, gave no de-
tectable red fluorescence. Reflecting the potential generality of
these findings, the ability of these co-oligomers to deliver a dif-
ferent siRNA for a different target protein [K6a siRNA (34) to
target keratin 6a expression] was also confirmed by a reduction in
target K6a mRNA levels in HaCaTcells as determined by quan-
titative reverse transcription PCR (SI Appendix, Fig. S4).
Preliminary mechanistic investigations suggest that these com-
plexes are internalized by an endosomal pathway rather than diffu-
sion through the cell membrane or pore formation. Untransfected
HaCaTcells, which did not express either of the fluorescent repor-
ter proteins, were treated with amphipathic co-oligomer 9a that
had been complexed with a Silencer® FAM™-Labeled Negative
Control siRNA(aFITC-labeled siRNA).Cellswere thenobserved
with a fluorescence microscope 4 h post treatment and 24 h post
treatment (SI Appendix, Fig. S5). At 4 h post treatment, punctate
green fluorescencewas clearly observed, consistentwithuptake via
an endosomal pathway. By 24 h, the green fluorescence was more
diffuse, as would be expected from endosomal escape allowing tar-
get knockdown. A small amount of punctate fluorescence re-
mained, implying that future incorporation of an endosomal
escape agent into the co-oligomer could further facilitate escape
and enable the use of lower siRNA doses (35).
Fig. 2. Reduction in tdTomato (tdTOM) fluorescence normalized to EGFP fluorescence in dual fluorescence reporter HaCaT cells by siRNA∶co-oligomer com-
plexes relative to untreated cells, as measured by flow cytometry. Prior to these experiments, cells had been sorted and >90% of the cells express both tdTOM
and EGFP. Results are of at least three separate experiments; each condition in triplicate. Error bars indicate SD. (A) Treatment of HaCaT cells with the ethyl,
hexyl, and dodecyl siRNA∶co-oligomer series. Treatments were 100 nM with respect to siRNA. (B) Dose-dependent reduction in tdTOM fluorescence by several
of the best performing co-oligomers.
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Mixtures of Amphipathic Carbonate Co-oligomers for the Delivery of
siRNA into HaCaT Cells and Primary Keratinocytes. In addition to the
diversity and, thus, tunability that can be rapidly achieved with
this step-economical co-oligomer synthesis strategy, including
incorporation of various hydrophobic side chains and initiator
moieties, two or more distinct co-oligomers can also be mixed
with one another to obtain even greater diversity in siRNA com-
plexation systems and thus in siRNA delivery (or other proper-
ties). To demonstrate this option, PEG-initiated co-oligomer 10
was mixed at various molar ratios with 9a, and then this mixture
was combined with siRNA and the resulting complex applied to
the dual fluorescence reporter HaCaT cells (Fig. 4A). PEG-
initiated co-oligomer 10 exhibits no siRNA delivery ability;
however, as the percentage of PEG-initiated 10 relative to 9a de-
creases, knockdown increases toward the values obtained for 9a
alone. Significantly, this strategy allows one to tune the size and
stability of the complexes as the DLS of the 10 and 9a com-
plexes with siRNA show a striking decrease in average size
and increase in stability by the addition of the PEG-initiated
co-oligomer 10, with all mixtures of 10 and 9a exhibiting average
sizes below 300 nm (Fig. 4B). The incorporation of PEG into
these siRNA∶co-oligomer complexes, and the resultant control
of size and stability are desirable for transitioning to in vivo ex-
periments and other applications (36).
These smaller and more stable siRNA∶co-oligomer complexes
were then examined for their ability to deliver siRNA and induce
knockdown in primary keratinocytes. Primary keratinocytes,
which had been transduced with the EGFP and Luc2/tdTOM
plasmids, were treated with a siRNA∶co-oligomer complex com-
posed of 95∶5 9a∶10 in a dose-dependent manner, resulting in up
to 79% knockdown, with significant knockdown (62%) at only
10 nM (Fig. 4C).
Cytotoxicity of the siRNA∶co-oligomer Complexes. To determine the
cytotoxicity of the siRNA∶co-oligomer complexes, HaCaT cells
were treated with siRNA∶co-oligomer complexes and then ana-
lyzed colorimetrically for mitochondrial reduction of methylthia-
zolyl-diphenyltetrazolium bromide (MTT) relative to untreated
cells (SI Appendix, Fig. S6). While this study was designed to
explore complexation, uptake, and release and not to minimize
toxicity, most of the amphipathic co-oligomer complexes were re-
latively nontoxic to HaCaT cells at the tested concentrations.
Some co-oligomer complexes did display some cytotoxicity but
only at the highest concentrations tested (100 nM with respect
to siRNA). Importantly, lowering the dose from 100 nM to
50 nM substantially reduces the cytotoxicity of even the most
active co-oligomer complexes, conditions which only slightly at-
tenuate the knockdown efficacy. In addition, exchange of the
counterion from TFA to chloride reduces cytotoxicity without
affecting knockdown efficiency.
Further underscoring the value of biodegradative release,
when the siRNA∶co-oligomer complexes were pre-incubated
in PBS (pH ¼ 7.4, 37 °C) for 24 h (conditions which were shown
by gel electrophoresis to result in degradation of the complex), no
Fig. 3. Fluorescence microscopy of tdTomato (tdTOM) fluorescence and
EGFP fluorescence in dual fluorescence reporter HaCaT cells treated with
siRNA∶co-oligomer complexes. Prior to these experiments, cells had been
sorted and >90% of the cells express both tdTOM and EGFP. Treatments were
100 nM with respect to siRNA. The left panel is the green channel only, the
middle panel is the red channel only, and the right panel is an overlay of the
brightfield image, red channel, and green channel. The scale bar is 10 μm.
Fig. 4. tdTOM reduction in HaCaT cells and primary keratinocytes by and DLS of siRNA∶co-oligomer complexes made from various molar percentage mixtures
of 9a and 10. The percentages are molar percentages out of a total molar ratio of 1∶52.5 siRNA∶co-oligomer. (A) Co-oligomers 9a and 10were mixed at various
molar ratios and then mixed with siRNA. The resulting complexes were applied to cells and analyzed by flow cytometry. Results are of at least three separate
experiments; each condition in triplicate. Error bars indicate SD. (B) DLS data on the siRNA∶co-oligomer complexes made from mixtures of 9a and 10 with
siRNA. The value shown is the average of three separate trials; error is SD. (C) Primary keratinocytes were treated with siRNA∶co-oligomer complexes composed
of 95∶5 9a∶10 in a dose-dependent manner. The value shown is the average of three separate trials. Error is SD.
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cytotoxicity was observed. That the amphipathic co-oligomers de-
grade readily after delivery to nontoxic components could render
these particular carriers attractive for local delivery and could
lead to improved clearance and reduced toxicity in vivo.
Conclusion
The first members of a new class of block and statistical guani-
dinium-rich amphipathic carbonate co-oligomers have been
designed, synthesized, and evaluated for siRNA delivery. These
amphipathic co-oligomers noncovalently complex, deliver, and
release siRNA into cells, resulting in up to 90% knockdown (with
an average of 86%) of a selected target protein by the best first-
generation oligocarbonates evaluated thus far. The organocata-
lytic oligomerization strategy for accessing these co-oligomers is
time and step-economical (one to two steps), metal-free, and
readily modified for optimizing delivery. By varying the proper-
ties (lipid length) of the monomers used, the properties of the
initiator, the relative ratios of the monomers incorporated,
and the overall co-oligomer length (DP), the physical properties
(e.g., particle size, stability, release rate), and therefore the
performance of the co-oligomers, can be tailored for various ap-
plications. The performance of the siRNA∶co-oligomer com-
plexes can be further controlled by mixing two or more distinct
co-oligomers. The biodegradability of these co-oligomers is a dis-
tinct advantage of this delivery system and is likely to figure in
future in vivo applications. The knowledge derived from this ap-
proach could be directly employed in various applications or
translated as needed to the preparation of discrete transporters
(e.g., amphipathic peptides and peptoids) made through conven-
tional (albeit longer) resin-based or solution-phase synthetic pro-
cedures, or to other backbones that can be accessed through
organocatalytic oligomerizations. The results of this study,
coupled with the ease with which siRNA delivery vectors can
be assembled, provide the basis for the broader use of this tech-
nology in kit format. The combination of this technology with
other delivery techniques [such as microneedles (37) or laser skin
ablation (38)] offers further opportunities to achieve therapeuti-
cally relevant siRNA delivery. The work reported herein has di-
rect applicability to in vitro siRNA studies and therapies, based
on local administration.
Materials and Methods
Additional supplemental figures and tables, information about materials and
instrumentation, synthetic procedures, compound characterization data, and
experimental details for cellular assays and for the formation and character-
ization of siRNA∶co-oligomer complexes can be found in SI Appendix.
ACKNOWLEDGMENTS. We thank Prof. Christopher Contag and Prof. Lynette
Cegelski for support with materials and equipment; Janus Haagensen for
training on the Leica confocal microscope and help with image processing;
Prof. Richard Zare for the use of the Malvern Zetasizer; Prof. Thomas
Wandless for use of a plate reader; and the FACS facility (Stanford), the mass
spectrometry facility (Stanford), and the NMR facility (Stanford) for instru-
mentation. Support of this work through grants NSF-CHE-0957386 (R.M.W.),
RC2AR058955 (R.L.K.), NIH-CA31841 (P.A.W.), and NIH-CA31845 (P.A.W.) from
the National Science Foundation and the National Institutes of Health are
acknowledged. Support of this work through fellowships from the National
Science Foundation (E.I.G.), Stanford Graduate Fellowship (E.I.G.), and IBM
(C.B.C.) is acknowledged.
1. Leung KM, Whittaker PA (2005) RNA interference: From gene silencing to gene-
specific therapeutics. Pharmacol Ther 107:222–239.
2. LaresMR, Rossi JJ, Ouellet DL (2010) RNAi and small interfering RNAs in human disease
therapeutic applications. Trends Biotechnol 28:570–579.
3. Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK (2011) RNA interference
in the clinic: Challenges and future directions. Nat Rev Cancer 11:59–67.
4. Castanotto D, Rossi JJ (2009) The promises and pitfalls of RNA-interference-based
therapeutics. Nature 457:426–433.
5. Davidson BL, McCray PB (2011) Current prospects for RNA interference-based
therapies. Nat Rev Genet 12:329–340.
6. Aagaard L, Rossi JJ (2007) RNAi therapeutics: Principles, prospects, and challenges.Adv
Drug Deliv Rev 59:75–86.
7. Elbashir SM, et al. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in
cultured mammalian cells. Nature 411:494–498.
8. Burnett JC, Rossi JJ, Tiemann K (2011) Current progress of siRNA/shRNA therapeutics in
clinical trials. Biotechnol J 6:1130–1146.
9. Leachman SA, et al. (2010) First-in-human mutation-targeted siRNA phase 1b trial of
an inherited skin disorder. Mol Ther 18:442–446.
10. Karkare S, Bhatnagar D (2006) Promising nucleic acid analogs and mimics: Character-
istic features and applications of PNA, LNA, and morpholino. Appl Microbiol Biotech-
nol 71:575–586.
11. Bruno K (2011) Using drug-excipient interactions for siRNA delivery. Adv Drug Deliv
Rev 63:1210–1226.
12. Hsu T, Mitragotri S (2011) Delivery of siRNA and other macromolecules into skin and
cells using a peptide enhancer. Proc Natl Acad Sci USA 108:15816–15821.
13. Tan SJ, Kiatwuthinon P, Roh YH, Kahn JS, Luo D (2011) Engineering nanocarriers for
siRNA delivery. Small 7:841–856.
14. Wang J, Lu Z, Wientjes MG, Au JLS (2010) Delivery of siRNA therapeutics: Barriers and
carriers. AAPS J 12:492–503.
15. Schroeder A, Levins CG, Cortez C, Langer R, Anderson DG (2009) Lipid-based nano-
therapeutics for siRNA delivery. J Int Med 267:9–21.
16. Davis ME (2009) The first targeted delivery of siRNA in humans via a self-assembling,
cyclodextrin polymer-based nanoparticle: From concept to clinic. Mol Pharm
6:659–668.
17. Reischl D, Zimmer A (2009) Drug delivery of siRNA therapeutics: Potentials and limits
of nanosystems. Nanomedicine 5:8–20.
18. Jeong JH, Mok H, Oh YK, Park TG (2009) siRNA conjugate delivery systems. Bioconjug
Chem 20:5–14.
19. Liu Z, Tabakman S,Welsher K, Dai H (2009) Carbon nanotubes in biology andmedicine:
In vitro and in vivo detection, imaging, and drug delivery. Nano Res 2:85–120.
20. Eguchi A, et al. (2009) Efficient siRNA delivery into primary cells by peptide trans-
duction-dsRNA binding domain. Nat Biotechnol 27:567–571.
21. Medarova Z, Pham W, Farrar C, Petkova V, Moore A (2007) In vivo imaging of siRNA
delivery and silencing in tumors. Nat Med 13:372–377.
22. Akhtar S, Benter IF (2007) Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest
117:3623–3632.
23. Wender PA, et al. (2000) The design, synthesis, and evaluation of molecules that
enable or enhance cellular uptake: Peptoid molecular transporter. Proc Natl Acad
Sci USA 97:13003–13008.
24. Wender PA, Cooley CB, Geihe EG (2012) Beyond cell penetrating peptides: Designed
molecular transporters. Drug Discov Today Technol 9:e49–e55.
25. Wender PA, Galliher WC, Goun EA, Jones LR, Pillow TH (2008) The design of guani-
dinium-rich transporters and their internalization mechanisms. Adv Drug Delivery
Rev 60:452–472.
26. Cooley CB, et al. (2009) Oligocarbonate molecular transporters: Oligomerization-
based syntheses and cell-penetrating studies. J Am Chem Soc 131:16401–16403.
27. Fukushima K, et al. (2008) Organocatalytic approach to amphiphilic comb-block
copolymers capable of stereocomplexation and self-assembly. Biomacromolecules
9:3051–3056.
28. Kim SH, et al. (2011) Thermoresponsive nanostructured polycarbonate block copoly-
mers as biodegradable therapeutic delivery carriers. Biomaterials 32:5505–5514.
29. Nederberg F, et al. (2011) Biodegradable nanostructures with selective lysis of micro-
bial membranes. Nat Chem 3:409–414.
30. Pratt RC, Nederberg F, Waymouth RM, Hedrick JL (2008) Tagging alcohols with cyclic
carbonate: A versatile equivalent of (meth)acrylate for ring-opening polymerization.
Chem Commun 114–116.
31. Choi HS, Kim HH, Yang JM, Shin S (2006) An insight into the gene delivery mechanism
of the arginine peptide system: Role of the peptide/DNA complex size. Biochim Bio-
phys Acta 1760:1604–1612.
32. Hickerson RP, et al. (2011) Use of self-delivery siRNAs to inhibit gene expression in an
organotypic pachyonychia congenital model. J Invest Dermatol 131:1037–1044.
33. Gonzalez-Gonzalez E, et al. (2009) siRNA silencing of keratinocyte-specific GFP expres-
sion in a transgenic mouse skin model. Gene Ther 16:963–972.
34. Smith FJ, et al. (2008) Development of therapeutic siRNAs for pachyonychia congenita.
J Invest Dermatol 128:50–58.
35. Siprashvili Z, et al. (2003) Gene transfer via reversible plasmid condensation with
cysteine-flanked, internally spaced arginine-rich peptides. Hum Gene Ther
14:1225–1233.
36. Knop K, Hoogenboom R, Fischer D, Schubert US (2010) Poly(ethylene glycol) in drug
delivery: Pros and cons as well as potential alternatives. Angew Chem Int Ed
49:6288–6308.
37. Gonzalez-Gonzalez E, et al. (2010) Silencing of reporter gene expression in skin using
siRNAs and expression of plasmid DNA delivered by a soluble protrusion array device.
Mol Ther 18:1667–1674.
38. Prausnitz MR, Langer R (2008) Transdermal drug delivery. Nat Biotechnol
26:1261–1268.
13176 ∣ www.pnas.org/cgi/doi/10.1073/pnas.1211361109 Geihe et al.
